Last reviewed · How we verify
OMP-21M18
At a glance
| Generic name | OMP-21M18 |
|---|---|
| Sponsor | OncoMed Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors (PHASE1)
- A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer (PHASE1)
- A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian (PHASE1)
- A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer (PHASE1)
- A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer (PHASE1)
- A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMP-21M18 CI brief — competitive landscape report
- OMP-21M18 updates RSS · CI watch RSS
- OncoMed Pharmaceuticals, Inc. portfolio CI